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Abstract
AIM: The effects of vitamin D3 have been investigated 
on various tumors, including colorectal cancer (CRC). 
25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the 
enzyme that inactivates the active vitamin D3 metabo-
lite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered 
to be the main enzyme determining the biological half-
life of 1,25-D3. During colorectal carcinogenesis, the 
expression and concentration of CYP24A1 increases 
significantly, suggesting that this phenomenon could be 
responsible for the proposed efficacy of 1,25-D3 in the 
treatment of CRC. The aim of this study was to investi-
gate the anti-tumor effects of vitamin D3 on the human 
CRC cell line Caco-2 after inhibition of the cytochrome 
P450 component of CYP24A1 activity. 
METHODS: We examined the expression of CYP24A1 
mRNA and the effects of 1,25-D3 on the cell line 
Caco-2 after inhibition of CYP24A1. Cell viability and 
proliferation were determined by means of sulforhoda-
mine-B staining and bromodeoxyuridine incorporation, 
respectively, while cytotoxicity was estimated via the 
lactate dehydrogenase content of the cell culture su-
pernatant. CYP24A1 expression was measured by real-
time reverse transcription polymerase chain reaction. 
A number of tetralone compounds were synthesized to 
investigate their CP24A1 inhibitory activity.
RESULTS: In response to 1,25-D3, CYP24A1 mRNA 
expression was enhanced significantly, in a time- and 
dose-dependent manner. Caco-2 cell viability and pro-
liferation were not influenced by the administration 
of 1,25-D3 alone, but were markedly reduced by co-
administration of 1,25-D3 and KD-35, a CYP24A1-inhib-
iting tetralone. Our data suggest that the mechanism of 
action of co-administered KD-35 and 1,25-D3 does not 
involve a direct cytotoxic effect, but rather the inhibi-
tion of cell proliferation. 
CONCLUSION: These findings demonstrate that the 
selective inhibition of CYP24A1 by compounds such as 
KD-35 may be a new approach for enhancement of the 
anti-tumor effect of 1,25-D3 on CRC.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Epidemiologic studies have suggested that maintenance 
of  an adequate level of  vitamin D may reduce the inci-
dence and development of  several types of  tumors, in-
cluding breast, prostate and colorectal cancers (CRC)[1-4]. 
The role of  vitamin D deficiency in the development of  
CRC, and the potential use of  vitamin D in the treatment 
of  CRC have been the focus of  a number of  studies, as 
CRC is one of  the most common cancers[5].
There is a vast array of  evidence suggesting a protec-
tive effect of  vitamin D against CRC[6-8]. There is an in-
verse association between the serum level of  25-hydroxy 
vitamin D3 (25-D3) and the risk of  CRC[1,9]. In ulcerative 
colitis, low expression of  the vitamin D receptor (VDR) 
is associated with an elevated risk of  the development of  
CRC[10]. An inadequate dietary intake of  vitamin D and 
a vitamin D deficiency promote the development and 
growth of  CRC in mice[3,11]. In elderly women, higher 
plasma levels of  25-D3 are accompanied by a lower risk 
of  CRC[12]. Further studies have shown that vitamin D 
may have a preventive role not only in CRC, but also in 
other cancers of  the alimentary tract[13]. Nevertheless, the 
exact cellular pathway for the putative anti-tumor effect 
of  vitamin D remains unclear. The action of  1,25-dihy-
droxyvitamin-D3 (1,25-D3) through the nuclear VDRs is 
delayed, but the immediate responses triggered from the 
cell by cytosolic VDRs acting through Ca2+ influx might 
also play an important role in this process[14]. However, 
the application of  1,25-D3 in tumor treatment is restrict-
ed due to its tendency to cause hypercalcemia[15].
The anti-tumor efficacy of  vitamin D in tumor cell 
cultures is somewhat contradictory[16-19]. Some cancer cell 
lines are more susceptible to vitamin D treatment than 
others[19,20], and the vitamin D-sensitive cell cultures have 
been shown to resemble early-stage tumors[20]. During 
the progression of  the cancer, this susceptibility is gradu-
ally lost, but the underlying pathophysiological process 
of  this loss is not clear. Though numerous clinical stud-
ies have been conducted with vitamin D or its analogs, 
the anti-tumor results were largely disappointing[21]. The 
current evidence suggests that a relationship does exist 
between vitamin D and cancer, but the strength of  this 
relationship appears to weaken on progression from the 
preclinical to the clinical situation[22]. Thus, further exami-
nations are needed to identify factors influencing the anti-
tumor effect of  vitamin D on tumor cells.
The mitochondrial enzyme cytochrome P450 com-
ponent of  25-hydroxyvitamin-D3-24-hydroxylase (CY-
P24A1), which is the major 1,25-D3-inactivating enzyme, 
is considered to be an essential factor determining the 
biological half-life of  1,25-D3. Previous immunohisto-
chemical studies have shown that the level of  CYP24A1 
rises significantly as the course of  colorectal carcinogen-
esis progresses[20,23]. This fact might explain why 1,25-D3 
cannot exert its anti-tumor effect in many pathological 
situations. It has also been demonstrated that the higher 
the level of  CYP24A1, the more malignant the CRC[24]. A 
concomitantly increased expression of  the proliferation 
marker Ki-67 in human CRC samples suggests that the 
overexpression of  CYP24A1 reduces the local availability 
of  1,25-D3, and hence its antiproliferative effect[24]. Other 
mechanisms to may be involved in the development of  
1,25-D3 insensitivity such as the downregulation of  the 
VDRs[25].
In the present study, we set out to investigate the ef-
fects of  1,25-D3 on CRC cells after the inhibition of  
CYP24A1 activity.
MATERIALS AND METHODS
CYP24A1 inhibitors
The ability of  tetralones to inhibit CYP24A1 is less than 
that of  their azole counterparts, but a greater degree of  
selectivity can be achieved with tetralones through the 
mechanism of  their binding to the active site. Instead of  
binding to the heme iron, they interact with the active 
site if  the enzyme through hydrogen bonds and van der 
Waals forces[26]. Thirteen new 2-substituted-benzyl-6-
methoxy-1-tetralones synthesized in the Department of  
Organic Chemistry in Szeged were utilized in the present 
study. 
The method employed for the preparation of  the 
tetralones[27] involved the condensation of  commercially 
available 6-methoxy-1-tetralone with benzaldehyde or 
a substituted benzaldehyde (Figure 1). 6-methoxy-1-te-
tralone (1) was dissolved in 4% ethanolic KOH solution, 
the appropriate benzaldehyde (2a-m) was added, and the 
reaction mixture was stirred at room temperature for 1-8 
h until the starting material had disappeared (thin layer 
chromatography monitoring), and then allowed to stand 
overnight. The precipitate that formed was filtered off, 
washed with water, purified by flash chromatography on 
silica gel, and recrystallized from ethanol. The synthesis 
of  the hydroxy derivative necessitated initial protection 
of  the hydroxy group in the 4-hydroxybenzaldehyde 
with a tetrahydropyranyl group, which was stable under 
the basic ethanolic KOH condensation conditions. The 
protecting group was removed by heating with aqueous 
hydrochloric acid in a mixture of  ethyl acetate and ethyl 
methyl ketone. In the next step, the 2-substituted-benzyl-
idene-6-methoxy-1-tetralones (3a-m) were dissolved in 
ethyl acetate, and hydrogenated at 1 atm in the presence 
of  Pd/C as catalyst for 1 h at room temperature. The 
catalyst was subsequently removed by filtration through a 
bed of  silica gel, the solvent was evaporated in vacuo, and 
purification by flash chromatography on silica gel fur-
nished the 2-substituted-benzyl-6-methoxy-1-tetralones 
(4a-m).
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The resulting tetralones were dissolved individually in 
dimethyl sulfoxide at a concentration of  10 mmol/L and 
stored at 4 ℃ until use. In cell culture experiments, com-
pounds (4a-m) were dissolved in sterile culture medium 
(GIBCO’s OPTI-MEM, Life Technologies-Invitrogen, 
Carlsbad, CA, United States) to the desired concentra-
tion. 1,25-D3 at 1 and 10 nmol/L and an untreated con-
trol were also applied in these experiments.
Cell culturing
The human epithelial colorectal adenocarcinoma cell 
line Caco-2 obtained from ECACC was maintained in 
Dulbecco’s Modified Eagle Medium (D-MEM, Sigma, St. 
Louis, MO, United States) supplemented with 10% fetal 
calf  serum (FCS, Sigma) and 1% antibiotic, antimycotic 
solution (Sigma) at 37 ℃ in a humidified atmosphere 
containing 5% CO2. Cells were cultured in 6-, 24- and 
96-well plates, and all measurements were carried out in 
triplicate. The cell line was genotyped and identified as 
Caco-2 in 2011 on the basis of  the results of  STR analy-
sis (DSMZ Profile Database, www.dsmz.de). Twenty-
four hours before treatment, the medium was changed 
to GIBCO’s OPTI-MEM (Life Technologies-Invitrogen, 
Carlsbad, CA, United States). All experiments were car-
ried out with cells from passages 5-25. 
Cell viability assay
The protein dye sulforhodamine-B (SRB), was used to 
test various tetralone derivatives in various concentra-
tions for various incubation times in 96-well plates to 
determine the effects of  the compounds alone and in the 
presence of  1,25-D3 on the Caco-2 cell number. After re-
moval of  the culture medium, 100 μL of  trichloroacetic 
acid was used to fix the cells during an incubation period 
of  30 min. The plates were then rinsed 5 times with dis-
tilled water. The cells were stained with a 0.4% solution 
of  SRB (Sigma) in acetic acid for 30 min. After removal 
of  the excess dye solution the plates were rinsed 4 times 
with 1% acetic acid solution and allowed to dry at room 
temperature. The bound SRB was dissolved in unbuf-
fered Trisma-Sol and the plates were shaken for 5 min. 
The plates were measured in an Infinite M200 reader (Te-
can AG, Männedorf, Switzerland) at 520 nm.
Cytotoxicity measurement
Levels of  cytotoxicity were quantified after treatment 
through measurement of  the lactate dehydrogenase 
(LDH) levels in the wells by using the Cytotoxicity Detec-
tion KitPLUS (Roche, Indianapolis, IN, United States). The 
greater the number of  cells that die due to the cytotoxic 
effect, the higher the amount of  LDH in the medium. 
The experiments were carried out in accordance with the 
kit manufacturer’s instructions.
Cell proliferation assays
Cell proliferation was quantified by measurement of  the 
incorporation of  5-bromo-2’-deoxyuridine (BrdU) into 
the cellular DNA by means of  Cell Proliferation enzyme-
linked immunosorbent assay, BrdU (colorimetric) (Roche). 
The experiments were carried out in accordance with the 
manufacturer’s instructions.
RNA isolation and Taqman probe-based real-time RT-
PCR
RNA was isolated through use of  the High Pure RNA 
Isolation Kit (Roche) as prescribed in the manufacturer’
s instructions. The isolated RNA was translated by using 
Moloney murine leukemia virus reverse transcriptase in 
accordance with the manufacturer’s instructions (Pro-
mega, Madison, WI, United States). Predesigned and 
validated gene-specific TaqMan Gene Expression Assays 
from Life Technologies (Life Technologies, Foster City, 
CA, United States) were used in triplicate for quantitative 
real-time polymerase chain reaction (PCR) according to 
the manufacturer’s protocol. Each set contained gene-
specific forward and reverse primers and fluorescence-
labeled probes. The probes span an exon junction and do 
not detect genomic DNA [ABI Taqman assay No’s are 
hs00167999_m1 and hs99999905_m1, for CYP24A1 and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
respectively]. The PCR assays were carried out with the 
following protocol: denaturation for 10 min at 95 ℃, 
and 45 cycles of  denaturation for 15 s at 95 ℃, anneal-
ing and extension for 1 min at 60 ℃. The PCR reaction 
volume of  20 μL contained 2 μL cDNA, 10 μL of  Taq-
Man 2x Universal PCR Master Mix NoAmpErase UNG 
(Life Technologies), 1 μL of  gene-specific TaqMan Gene 
Expression Assay Mix and 7 μL of  water. GAPDH was 
used as a housekeeping gene to normalize for RNA load-
ing. Samples were analyzed using the ABI Prism 7500 
real-time PCR system (Life Technologies). Relative quan-
tification (RQ) studies were carried out on collected data 
(threshold cycle numbers, referred to as Ct) with the 7500 
System SDS software 1.3 (Life Technologies).
Statistical analysis
Data were analyzed by using SPSS for Windows, release 
18 (IBM, Armonk, NY, United States). Final data are pre-
sented as the means ± SD of  at least three independent 
measurements. Statistical analysis was performed with the 
unpaired Student t-test; results with P ≤ 0.05 were con-
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Figure 1  Outline of the procedure for the synthesis of the tetralones. 
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sidered statistically significant.
RESULTS
Time and concentration-dependent changes in CYP24A1 
mRNA expression after vitamin D3 treatment
An increase in CYP24A1 mRNA level of  six orders of  
magnitude was observed after a brief  period of  1,25-D3 
treatment. The increase in CYP24A1 mRNA expression 
was very rapid and it could be observed after 30 min of  
1,25-D3 administration, and reached a maximum after 
12-16 h of  incubation (Figure 2A). After 4 h of  incuba-
tion in the presence of  1 and 10 nmol/L 1,25-D3, the 
level of  CYP24 mRNA was elevated to 311405-fold and 
612801-fold, respectively, relative to the untreated con-
trols (Figure 2B). 
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Figure 2  Time and dose dependent-changes in CYP24A1 mRNA expres-
sion in response to 1,25-D3 administration. A: Time course of changes in 
the cytochrome P450 component of the 25-hydroxyvitamin D3-24-hydroxylase 
(CYP24A1) mRNA expression in Caco-2 cells after the addition of 100 nmol/L 
active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3) to the cell 
culture supernatant. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-
normalized CYP24A1 expression levels are shown as a percentage of the 
CYP24A1 level of the untreated control cells. Points indicate means ± standard 
deviation (SD) (aP < 0.05 vs untreated control); B: Dose-dependent changes in 
CYP24A1 mRNA levels in Caco-2 cells after the addition of different amounts 
of 1,25-D3. GAPDH-normalized CYP24A1 expression levels are shown as a 
percentage of the CYP24A1 level of the untreated control cells. Points indicate 
means ± SD (aP < 0.05 vs untreated control).
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Figure 3  Cell proliferation, lactate dehydrogenase activity and prolifera-
tion studies in the presence of KD-35 and 1,25-D3. A: Changes in the num-
ber of viable Caco-2 cells (sulforhodamine-B staining) in the presence of differ-
ent concentrations of KD-35. Selected wells were treated with 100 nmol/L active 
1,25-D3. Data are means ± SD (aP < 0.05 between KD-35 and KD-35 + 1,25-D3 
treated cells); B: Changes in the lactate dehydrogenase (LDH) activity of the 
cell culture supernatant in response to KD-35 with or without 1,25-D3. Data 
are means ± SD. No significant changes in LDH activity were seen after treat-
ment; C: Changes in the proliferation of Caco-2 cells (5-bromo-2’-deoxyuridine 
incorporation) in response to different concentrations of 1,25-D3. White bars 
indicate combined treatment with the given 1,25-D3 concentration + 2 μmol/L 
KD-35. Data are means ± SD. Significance levels were calculated between 
each sample and the untreated control sample (aP < 0.05 between 1,25-D3 and 
1,25-D3 + KD-35 treated cells).
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Effects of tetralone derivatives on Caco-2 cell line
Certain of  the tetralones were found to decrease the 
Caco-2 cell viability but only after 2-4 d of  incubation 
with 1,25-D3. These compounds were tested at various 
concentrations for various periods to optimize the ef-
fect of  1,25-D3 in reducing the total Caco-2 cell count. 
Finally, compound KD-35 was selected for further and 
detailed investigations. 
Effects of KD-35 on Caco-2 cell line
When Caco-2 cells were incubated for 4 d in the presence 
of  100 nmol/L 1,25-D3 with 0.1, 0.3, 1 or 3 μmol/L 
KD-35, the cell number was reduced by 2.17%, 5.07%, 
6.18% and 10.93%, respectively, relative to the controls 
treated with only 100 nmol/L 1,25-D3 or 3 μmol/L 
KD-35 (Figure 3). 
Results of the cytotoxicity test
To determine the cause of  the decrease in viable cell 
number in the presence of  KD-35 and 1,25-D3, we mea-
sured LDH concentration in the cell suspension. The 
concentration of  KD-35 ranged between 0.04 μmol/L 
and 5 μmol/L. Half  of  the wells were treated with 
KD-35 and 100 nmol/L 1,25-D3, the other half  were 
treated with KD-35 only. All experiments were carried 
out in triplicate. Incubation lasted for 4 d. In all of  the 
experimental setups, the LDH concentrations did not 
differ significantly in the presence of  KD-35 alone or in 
combination with 1,25-D3 (Figure 3). 
Results of the cell proliferation assay
In the presence of  2 μmol/L KD-35, the following con-
centrations of  1,25-D3 were used: 7.4, 22.2, 66.6 and 
200 nmol/L. Half  of  the wells were treated only with 2 
μmol/L KD-35. Incubation lasted for 4 d. After incuba-
tion, the 5-BrdU label was added for an additional 2 h. 
The reduction in cell number relative to the control was 
3.43%, 14.81%, 22.49% and 35.81%, respectively, com-
pared to the wells with 1,25-D3 only (Figure 3). 
Changes in CYP24A1 mRNA expression
The amount of  CYP24A1 mRNA expressed in the pres-
ence of  various concentrations of  KD-35 did not dif-
fer from that of  the untreated controls. The CYP24A1 
mRNA expression did not depend significantly on the 
duration of  incubation with KD-35 (Figure 4). 
DISCUSSION
We have identified a new tetralone compound, KD-35, 
that effectively and markedly stimulates the anti-prolifera-
tive effect of  1,25-D3 in the CRC cell line Caco-2. 
CYP24A1, a member of  the cytochrome P450 (CYP450) 
enzyme superfamily is the key enzyme in the metabolism 
of  vitamin D neutralizing the active metabolite 1,25-D3, 
and thereby controlling its concentration in the tissues. 
The CYP450 enzymes all display an iron-containing heme 
domain at the active site. There are two types of  enzyme 
blockers: azoles and non-azoles[28]. The N-heterocyclic 
ring of  azoles is linked directly to the iron in the heme do-
main and, although this inhibition is very potent, it is not 
selective. Since the other enzymes involved in vitamin D 
metabolism (CYP27A1 and CYP27B1) are also members 
of  the CYP450 superfamily, this type of  nonselective inhi-
bition is not specific for CYP24A1.
The enzyme inhibitory effect of  non-azoles is medi-
ated through hydrogen bonds and hydrophobic interac-
tions with the active site of  the enzyme. This is a more 
flexible mechanism which may permit significant selectiv-
ity though the inhibitory effect may be less than that of  
azoles[26]. We investigated 13 tetralones (non-azoles) in 
a search for a compound that is effective locally in the 
colon and is not strongly absorbed, so that the risk of  
adverse systemic effects is minimized.
Most of  the 13 tetralones were either toxic or inef-
fective, even in the presence of  1,25-D3. Only in the 
presence of  KD-35 did 1,25-D3 markedly inhibit Caco-2 
cell proliferation without pronounced cytotoxicity of  
the tetralone alone. Such inhibition was not observed in 
the absence of  KD-35. Unfortunately, two of  the three 
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most effective tetralones exhibited much higher cytotox-
icity at higher concentrations than KD-35. The question 
arises as to whether KD-35 exerts its effect via CYP24A1 
inhibition. We did not measure CYP24A1 enzyme activ-
ity directly since this is technically extremely difficult. It 
is also complicated to measure the intermediates of  the 
CYP24A1 reaction. Moreover, a simple enzyme kinetic 
measurement would not reveal whether the compound 
enters the cell. We therefore chose an indirect approach: 
to prove the biological efficacy of  the compound. KD-35 
was found to exert an effect that allowed 1,25-D3 to re-
duce Caco-2 cell proliferation effectively, as reflected by 
an altered BrdU incorporation. Direct cytotoxicity was 
excluded by the LDH measurements, and no change in 
CYP24A1 mRNA expression was detected in response to 
KD-35, which ruled out alterations in protein synthesis. 
Obviously, no direct evidence was obtained to support 
direct enzyme inhibition, but an alternative mechanism is 
highly unlikely with this non-azole.
Two major pathways are mediated through the VDRs: 
the Wnt-beta-catenin pathway, which is responsible for 
the loss of  adherent cell type, and the E-cadherin path-
way, which is responsible for cell-to-cell adhesion and cell 
differentiation[29,30]. The administration of  1,25-D3 sup-
presses the Wnt-beta-catenin pathway and induces the 
expression of  E-cadherin. The Wnt-beta-catenin pathway 
is constitutionally overregulated in most CRCs, due to 
the mutation of  several members of  the pathway (APC, 
AXIN2, etc.)[29]. There are other participants in colorectal 
carcinogenesis, such as estrogen receptors, which elevate 
the number of  VDRs in the mucosal cells of  the alimen-
tary tract, or SNAIL, which inhibits the E-cadherin path-
way and expression of  VDRs[30-35]. Another important 
factor in the mucosal cell transition toward adenocarci-
noma is an elevated level of  CYP24A1, the intracellular 
concentration of  which correlates with the dignity of  the 
tumor[24]. 
Our results corroborate the earlier finding[36] that the 
presence of  1,25-D3 dramatically stimulates the expres-
sion of  CYP24A1 in CRC cells[24,37]. Two vitamin D-re-
sponsive elements are present in the promoter region of  
CYP24A1[38]. Through this pathway, 1,25-D3 stimulates 
its own destruction through metabolism into inactive 
forms by enhancing the expression of  CYP24A1[39].
Besides the genomic effects, there have also been 
reports of  immediate nongenomic mechanisms. A pos-
sible mode of  action is activation of  the RhoA-ROCK-
p38MAPK-MSK signaling pathway. This pathway medi-
ates the induction of  CST5, which is possibly responsible 
for tumor suppression and the level of  CYP24A1; as a 
negative feedback mechanism, this eliminates 1,25-D3 
from the cell[40]. VDRs found in other tumor cell mem-
branes may bind 1,25-D3, and the complex could induce 
a rapid influx of  Ca2+ into the cell[40], which activates 
RhoA-ROCK and then the p38MAPK-MSK-1 pathway. 
Besides the nongenomic activation of  this pathway, a 
vitamin D-responsive element can also be identified in 
the -1k promoter region of  the RhoA gene (http://www.
cbil.upenn.edu/cgi-bin/tess/tess). RhoA plays an impor-
tant role in the induction of  CDH1/E-cadherin, which 
is crucial for the acquisition of  the polarity and adhesive 
phenotype of  cancer cells[29]. 
In view of  these data, the elevation of  CYP24A1 
expression might be a self-defense mechanism of  tumor 
cells. By inhibiting the inactivating enzyme, the amount 
of  active vitamin D or its analogs required to elicit their 
marked anti-tumor effect could be reduced in vivo, thereby 
preventing elevation of  the serum Ca2+ level and avoiding 
hypercalcemia[36]. The inhibition of  CYP24A1 may allow 
1,25-D3 to exert its anti-tumor effect, in this way leading 
to a new approach in the treatment of  CRC in the future.
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